Table 2.
Approved liposomal formulations used in various applications.
| Product | Drug | Target Treatment | References |
|---|---|---|---|
| Doxil® | Doxorubicin | Breast and ovarian cancer | [7,65] |
| Marqibo® | Vincristine sulfate liposomes | Hodgkin’s lymphoma and leukemia | [66] |
| Arikayce® | Amikacin | MAC and PA infections | [67] |
| Lipoquin® | Ciprofloxacin | MAC infections | [68] |
| Pulmaquin® | Ciprofloxacin | PA lung infections | [68] |
| TOBI® | Tobramycin | PA infections | [69] |
| Cayston® | Aztreonam | Gram negative infections | [70] |
| Colobreathe® | Colistin | Gram negative infections | [71] |
| Ambisome® | Amphotericin B | Fungal infections | [72,73] |
| Exparel® | Bupivacaine | Pain management | [7] |
| Inflexal® | Inactivated hemagglutinin of influenza virus strains A and B | Influenza | [7] |
| Epaxal® | Formalin inactivated hepatitis A virus, strain RG-SB | Hepatitis A | [73] |
| Moderna COVID-19 | mRNA 1273 | Covid-19 | [74,75] |